ClinicalTrials.gg
RecruitingNCT05403177MOHCCN-OUpdated Jun 10, 2026

Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)

An observational study in Breast Cancer, Colorectal Cancer and Pancreas Cancer, sponsored by University Health Network, Toronto. Recruiting at 3 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by University Health Network, Toronto · Observational

How we know

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 67 studies in Breast Neoplasms by University Health Network, Toronto — 19 open to participants now, 23 under way, 1 of them phase 3. Breast Neoplasms · University Health Network, Toronto.

Planned enrollment
6th of 25
500 · median 180
Started
2022
with 3 others
Observational
25 of 67
9 open now
Primary completion
2030-04
later than 20 of 22 live
Registered
56th of 67
by date

Among the 67 studies in Breast Neoplasms by University Health Network, Toronto, this one is the 6th largest by planned enrollment of the 25 observational ones that give a count, is one of 4 that started in 2022, is one of 25 observational ones, reaches primary completion later than 20 of the 22 other live ones, and was the 56th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 67 studies in Breast Neoplasms by University Health Network, Toronto are open now, in 10 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Breast Neoplasms by University Health Network, Toronto, or all of them as a file.
02

Study summary

The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients

Read the detailed description

The purpose of this study is to use evolving technologies such as genomics and artificial intelligence to study cancer so that the right treatment can be given to the right patient, at the right time. Approximately 15,000 participants will take part in the greater MOHCCN study across Canada in the first 5 years, and ultimately the goal is to enroll up to 100,000 over next 10 years.

03

Conditions studied

  • Breast Cancer
  • Colorectal Cancer
  • Pancreas Cancer
  • Kidney Cancer
  • Prostate Cancer
  • Ovary Cancer
  • Head and Neck Cancer
  • Leukemia
  • Lymphoma
  • Lung Cancer
  • Melanoma
  • Solid Tumor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Any cancer patient

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with histological and/or cytological confirmation of blood or solid tumor . For tumour types where pre-surgical is not routinely performed to confirm a pathologic diagnosis of cancer, patients may consent to this protocol, but eligibility must be confirmed after pathology is finalized demonstrating presence of malignancy
  2. All patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through:

    1. Already existing data that satisfies the minimal requirements of a gold standard case (refer to Table 1)
    2. Have sufficient biospecimens (tumor and/or blood samples) available for more comprehensive molecular and immunophenotypic characterization
  3. Patients who do not satisfy the required minimum data elements but would like to participate, maybe requested to donate blood and undergo a fresh biopsy if the archived Formalin-fixed paraffin-embedded (FFPE) samples are not available, or in cases where a fresh tumor biopsy is deemed necessary for molecular profiling.
  4. Participating patients must agree to share their anonymized clinical and genomic data

Exclusion criteria

Exclusion Criteria:

None.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • MOHCCN-O

    Tumor tissue and blood samples will be collected from patients who are enrolled in this study but do not yet have the molecular profiling data that are required to meet the gold standard criteria. Data will include: pathology, clinical biomarkers, imaging diagnostic information, whole genome and epi-genome sequencing of tumor and normal tissues, immunoprofiling of tumor tissues and/or peripheral blood, bioinformatic annotation of molecular information, and longitudinal clinical and outcome data.

06

What researchers measure

Primary outcomes

  1. Number of patients included in a pan-Canadian cohort with comprehensive clinical and genomic data

    Consolidate and annotate data from patients included in a pan-Canadian cohort

    Time frame: 5 years

Secondary outcomes

  1. Development of standard practices to create a unique shareable dataset of molecular, imaging, clinical and health outcome information on Canadian cancer cases

    Improve the cancer research paradigm by bringing teams or researchers together and leverage valuable information genomic and clinical data from Canadian cancer cases.

    Time frame: 5 years

  2. Clinical effectiveness and cost-effectiveness of precision cancer medicine to advance clinical implementation and reimbursement decisions

    Health technology assessment tools will be used to evaluate the real-world value of precision medicine

    Time frame: 5 years

  3. Development and collection of patient-reported outcomes to enhance patient-centeredness in precision cancer medicine

    Health technology assessment tools will be used to evaluate the real-world value of precision medicine

    Time frame: 5 years

07

Study locations

2 of 3 sites recruiting
  • Kingston Health Sciences Centre
    Kingston, Ontario K7L 2V7, Canada
    Recruiting
    • Heather Grant · Contactgranth@queensu.ca · 613-548-2517
    • Amber Simpson, PhD · Principal investigator
  • Ottawa Health Research Institute
    Ottawa, Ontario K1Y 4E9, Canada
    Not yet recruiting
    • Leonard Angka, PhD · Contactlangka@ohri.ca · 613-737-8899
    • Rebecca Auer, MD · Principal investigator
  • Princess Margaret Cancer Centre
    Toronto, Ontario M5G2M9, Canada
    Recruiting
    • PM2C Central Office · ContactMOHCCN@uhn.ca · 416-946-4501
    • Lillian Siu, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Apr 2030, 94 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 94 months is above that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2022
First posted
Jun 3, 2022
StartActual
Jun 23, 2022
Primary completionEst.
Apr 2030
CompletionEst.
Oct 2030
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05403177
Collaborators
Princess Margaret Hospital, Canada, Ontario Institute for Cancer Research, Terry Fox Research Institute, Queen's University, Kingston, Ontario, Ottawa Hospital Research Institute, Kingston Health Sciences Centre, Windsor Regional Hospital, University of Windsor, London Health Sciences Centre, London Health Sciences Centre Research Institute
Responsible party
Sponsor
First posted
Jun 3, 2022
Start date
Jun 23, 2022
Primary completion
Apr 2030 (estimated)
Completion
Oct 2030 (estimated)
Last update
Jun 10, 2026

Study contacts

PM2C Central Office
Contact
MOHCCN@uhn.ca
416-946-4501 ext. 3486
Lillian Siu, MD
principal investigator · University Health Network, Toronto

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion